2025 Bio Asia-Taiwan--Invitation to BPM booth

2025 Bio Asia-Taiwan

Bio Preventive Medicine Corp. (BPM) will participate in Bio Asia-Taiwan 2025, held from July 24 (Thursday) to July 27 (Sunday), 2025, at Taipei Nangang Exhibition Center, Hall 1, 4th Floor. We will be exhibiting at the Academia Sinica Pavilion, Booth N406 (co-exhibit) and Booth L418, showcasing our DNlite-IVD103 for diabetic kidney disease prognosis.

By 2040, the global diabetic population is projected to exceed 600 million. Among the complications, diabetic kidney disease (DKD) is both the most common and severe, and it is the leading cause of end-stage renal disease (ESRD) worldwide. In Taiwan, approximately 50% of ESRD cases are caused by DKD. However, current clinical indicators used in practice have limited ability to predict rapid kidney function decline in diabetic patients, often missing the optimal timing for early intervention. This has become an urgent clinical issue in the pursuit of precision medicine for diabetes care.

In response to this clinical need, BPM has been engaged in biomarker development since the national-level program was launched. Since our founding, we have been dedicated to translating this research into clinically applicable diagnostic tools. After more than a decade of in-house R&D, we introduced DNlite-IVD103, an innovative test kit protected by global patents.DNlite-IVD103 is a non-invasive urine test that effectively predicts the risk of kidney function deterioration within five years for diabetic patients. It enables early clinical intervention, slowing disease progression, and plays a key role in personalized care and early treatment strategies for diabetes.

Currently, DNlite-IVD103 has obtained Class III medical device certification from Taiwan’s TFDA for use in diabetic nephropathy and kidney transplant prognosis. It has also received IVD market approval in over 40 countries, including the EU, Asia, Australia, and Latin America. In 2024, DNlite-IVD103 was included in the "2024 Taiwan Clinical Practice Guidelines for Diabetic Kidney Disease" as a tool for personalized risk assessment of rapid kidney function decline in diabetic patients. Studies published by global clients in major medical journals and conferences have consistently demonstrated the test’s efficacy across multiple populations. We hope this innovation from Taiwan will benefit patients worldwide and help reduce the healthcare burden caused by ESRD.

Dr. Tseng, Tzu-Ling (Karen), CEO, and Ms. Jennifer Tseng, VP of Business and Marketing, will each give a presentation titled:
“Innovative Diagnostic for Kidney Disease Prevention: DNlite IVD-103 – Taiwan Clinical Guideline Inclusion & Market Outlook”
at Booth N406 (Academia Sinica Pavilion) during two sessions:

Friday, July 25 | 2:00 PM – 2:15 PM
Sunday, July 27 | 11:30 AM – 11:45 AM

We hope these talks will inspire and contribute to advancing kidney health for people with diabetes.